A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Cenobamate Adjunctive Therapy in Subjects With PGTC Seizures
Phase of Trial: Phase III
Latest Information Update: 06 Oct 2019
Price : $35 *
At a glance
- Drugs Cenobamate (Primary)
- Indications Generalised seizures; Tonic-clonic epilepsy
- Focus Registrational; Therapeutic Use
- Sponsors SK Life Science
- 18 Sep 2019 Planned End Date changed from 1 Nov 2021 to 19 Nov 2021.
- 18 Sep 2019 Planned primary completion date changed from 1 Nov 2021 to 19 Nov 2021.
- 07 Jan 2019 Status changed from not yet recruiting to recruiting.